MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Abstract
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited ef fi cacy observed for MEK inhibitors may involve adaptive feedback mechanisms through the reactivation of MAPK signalling caused by the blockade of ERK signalling [11 -13].”
In the citing paper
“Although RAS/RAF-mutated CRC has been targeted for the development of therapeutic inhibitors, they have been largely ineffective, likely due to complex resistance mechanisms such as intrinsic and adaptive resistance [5–12].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“However, MEK inhibitors, used alone, have been largely ineffective, likely due to intrinsic and adaptive resistance mechanisms [5–7].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“Previous studies demonstrated that the adaptive reactivation of MAPK signaling in the presence of a MEK inhibitor was mediated by the loss of MAPK-dependent negative feedback loops and the consequent induction of RTKs signaling (26, 53).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
In the citing paper
“targeting of MEK alone is frequently hampered by adaptive resistance, which is complex and context-dependent, and can involve activation of various RTKs, including ERBB family, AXL, PDGFR-α, or FGFR1 (26, 53, 59–62).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase
Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., & Ahn, N. G. (1994) · Science · doi:10.1126/science.8052857 · Cited by 1,353
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions
Yoon, S., & Seger, R. (2006) · Growth Factors · doi:10.1080/02699050500284218 · Cited by 1,273
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Meloche, S., & Pouysségur, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210414 · Cited by 1,091
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Scaffold Proteins: Hubs for Controlling the Flow of Cellular Information
Good, M. C., Zalatan, J. G., & Lim, W. A. (2011) · Science · doi:10.1126/science.1198701 · Cited by 885
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Self-citationRinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633
Regulation of Raf-1 by Direct Feedback Phosphorylation
Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., & Morrison, D. K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.055 · Cited by 633
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Integrating signals from RTKs to ERK/MAPK
McKay, M. M., & Morrison, D. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210394 · Cited by 621
Signalling ballet in space and time
Kholodenko, B. N., Hancock, J. F., & Kolch, W. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2901 · Cited by 614
Pratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614
Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., Rominger, C. M., Erskine, S., Fisher, K. E., Yang, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2200 · Cited by 587
Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D., Brandhuber, B. J., Gross, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578
Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome
Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F., & Rauen, K. A. (2006) · Science · doi:10.1126/science.1124642 · Cited by 571
Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., Hanson, L. J., Gore, L., Chow, L., Leong, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4956 · Cited by 570
Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.009 · Cited by 562
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1.
Alessi, D. R., Saito, Y., Campbell, D. G., Cohen, P., Sithanandam, G., Rapp, U., Ashworth, A., Marshall, C. J., & Cowley, S. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06424.x · Cited by 559
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., Sun, P., Moy, C., Szabo, S. A., Roadcap, L. T., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70269-3 · Cited by 546
Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling
Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535
Self-citationMathematical Models of Protein Kinase Signal Transduction
Heinrich, R., Neel, B. G., & Rapoport, T. A. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00528-2 · Cited by 511
A dimerization-dependent mechanism drives RAF catalytic activation
Rajakulendran, T., Sahmi, M., Lefrançois, M., Sicheri, F., & Therrien, M. (2009) · Nature · doi:10.1038/nature08314 · Cited by 489
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484
Self-citationKim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5966 · Cited by 477
The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells
Ramos, J. W. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.04.009 · Cited by 474
Targeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 468
Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008990107 · Cited by 449
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446
Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2339 · Cited by 446
Carvajal, R. D., Sosman, J. A., Quevedo, J. F., Milhem, M. M., Joshua, A. M., Kudchadkar, R. R., Linette, G. P., Gajewski, T. F., Lutzky, J., Lawson, D. H., et al. (2014) · JAMA · doi:10.1001/jama.2014.6096 · Cited by 433
Ascierto, P. A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R. F., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8691 · Cited by 432
Regulation and Role of Raf-1/B-Raf Heterodimerization
Rushworth, L. K., Hindley, A. D., O'Neill, E., & Kolch, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2262-2272.2006 · Cited by 418
Farley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O., Zoete, V., et al. (2012) · Nature Genetics · doi:10.1038/ng.1026 · Cited by 409
LoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401
The clinical development of MEK inhibitors
Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 400
Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues.
Zheng, C. F., & Guan, K. L. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06361.x · Cited by 398
Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0531 · Cited by 382
Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377
Infante, J. R., Somer, B. G., Park, J. O., Li, C.-P., Scheulen, M. E., Kasubhai, S. M., Oh, D.-Y., Liu, Y., Redhu, S., Steplewski, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 370
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 345
Giroux, S., Tremblay, M., Bernard, D., Cardin-Girard, J.-F., Aubry, S., Larouche, L., Rousseau, S., Huot, J., Landry, J., Jeannotte, L., et al. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80164-x · Cited by 341
Ebisuya, M., Kondoh, K., & Nishida, E. (2005) · Journal of Cell Science · doi:10.1242/jcs.02505 · Cited by 331
Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K., Price, S., Heald, R., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 319
Chen, J., Fujii, K., Zhang, L., Roberts, T., & Fu, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141224398 · Cited by 316
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B., Egyhazi, S., Hansson, J., Wu, H., King, A. J., Van Belle, P., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 309
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Bekaii-Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L., Kauh, J. S. W., O'Neil, B. H., Balsom, S., Balint, C., Liersemann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9473 · Cited by 303
Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302
Ribas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., Flaherty, L., Logan, T., Chmielowski, B., Lewis, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70301-8 · Cited by 299
Role of mitogen-activated protein kinase kinase kinases in signal integration
Cuevas, B. D., Abell, A. N., & Johnson, G. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210409 · Cited by 294
Cell fate decisions are specified by the dynamic ERK interactome
von Kriegsheim, A., Baiocchi, D., Birtwistle, M., Sumpton, D., Bienvenut, W., Morrice, N., Yamada, K., Lamond, A., Kalna, G., Orton, R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1994 · Cited by 286
MEK1/2 dual-specificity protein kinases: Structure and regulation
Roskoski, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.145 · Cited by 276
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262
Self-citationGenetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2223 · Cited by 255
LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1883 · Cited by 252
Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway
Mody, N., Leitch, J., Armstrong, C., Dixon, J., & Cohen, P. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02651-5 · Cited by 250
The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
Sturm, O. E., Orton, R., Grindlay, J., Birtwistle, M., Vyshemirsky, V., Gilbert, D., Calder, M., Pitt, A., Kholodenko, B., & Kolch, W. (2010) · Science Signaling · doi:10.1126/scisignal.2001212 · Cited by 247
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Ritt, D. A., Monson, D. M., Specht, S. I., & Morrison, D. K. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00569-09 · Cited by 238
Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9687-4 · Cited by 236
Eblen, S. T., Slack, J. K., Weber, M. J., & Catling, A. D. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6023-6033.2002 · Cited by 222
Marks, J. L., Gong, Y., Chitale, D., Golas, B., McLellan, M. D., Kasai, Y., Ding, L., Mardis, E. R., Wilson, R. K., Solit, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0099 · Cited by 211
Banerji, U., Camidge, D. R., Verheul, H. M. W., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M. E., Timmer-Bonte, J. N. H., Eckhardt, S. G., Lewis, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2483 · Cited by 211
Self-citationERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Hatzivassiliou, G., Liu, B., O'Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R., Forrest, W. F., Heldens, S., Chen, H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1010 · Cited by 211
Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 210
Self-citationCombined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
Chen, X., Wu, Q., Tan, L., Porter, D., Jager, M. J., Emery, C., & Bastian, B. C. (2014) · Oncogene · doi:10.1038/onc.2013.418 · Cited by 208
Xing, F., Persaud, Y., Pratilas, C. A., Taylor, B. S., Janakiraman, M., She, Q.-B., Gallardo, H., Liu, C., Merghoub, T., Hefter, B., et al. (2012) · Oncogene · doi:10.1038/onc.2011.250 · Cited by 207
Franco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
Chiariello, M., Marinissen, M. J., & Gutkind, J. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1747-1758.2000 · Cited by 195
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling
Fritsche‐Guenther, R., Witzel, F., Sieber, A., Herr, R., Schmidt, N., Braun, S., Brummer, T., Sers, C., & Blüthgen, N. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.27 · Cited by 192
Villanueva, J., Infante, J. R., Krepler, C., Reyes-Uribe, P., Samanta, M., Chen, H.-Y., Li, B., Swoboda, R. K., Wilson, M., Vultur, A., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.023 · Cited by 187
Zhang, Z., Kobayashi, S., Borczuk, A. C., Leidner, R. S., LaFramboise, T., Levine, A. D., & Halmos, B. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq020 · Cited by 186
Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors
Fischmann, T. O., Smith, C. K., Mayhood, T. W., Myers, J. E., Reichert, P., Mannarino, A., Carr, D., Zhu, H., Wong, J., Yang, R.-S., et al. (2009) · Biochemistry · doi:10.1021/bi801898e · Cited by 183
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
Iverson, C., Larson, G., Lai, C., Yeh, L.-T., Dadson, C., Weingarten, P., Appleby, T., Vo, T., Maderna, A., Vernier, J.-M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0679 · Cited by 183
A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal
Catalanotti, F., Reyes, G., Jesenberger, V., Galabova-Kovacs, G., de Matos Simoes, R., Carugo, O., & Baccarini, M. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1564 · Cited by 182
Mek2 Is Dispensable for Mouse Growth and Development
Bélanger, L.-F., Roy, S., Tremblay, M., Brott, B., Steff, A.-M., Mourad, W., Hugo, P., Erikson, R., & Charron, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.14.4778-4787.2003 · Cited by 181
Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179
Robert, C., Dummer, R., Gutzmer, R., Lorigan, P., Kim, K. B., Nyakas, M., Arance, A., Liszkay, G., Schadendorf, D., Cantarini, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70237-7 · Cited by 169
Halilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0409 · Cited by 168
Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T. E., Damyanov, D., Stella, P., Ganchev, H., Pover, G., Morris, C., & Tzekova, V. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e8b3a3 · Cited by 162
Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-26 · Cited by 152
Martinez-Garcia, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S., Kraeber-Bodéré, F., Rojo, F., Routier, E., Guarin, E., Xu, Z.-X., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0742 · Cited by 151
C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M., & Tuveson, D. A. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-10-0044 · Cited by 149
Friday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., & Adjei, A. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1430 · Cited by 146
Self-citationJohnson, G. L., Dohlman, H. G., & Graves, L. M. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.04.004 · Cited by 145
Carragher, L. A. S., Snell, K. R., Giblett, S. M., Aldridge, V. S. S., Patel, B., Cook, S. J., Winton, D. J., Marais, R., & Pritchard, C. A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000099 · Cited by 144
Self-citationBalmanno, K., Chell, S. D., Gillings, A. S., Hayat, S., & Cook, S. J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24604 · Cited by 143
Self-citationMAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
Arcila, M. E., Drilon, A., Sylvester, B. E., Lovly, C. M., Borsu, L., Reva, B., Kris, M. G., Solit, D. B., & Ladanyi, M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2124 · Cited by 142
Eblen, S. T., Slack-Davis, J. K., Tarcsafalvi, A., Parsons, J. T., Weber, M. J., & Catling, A. D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.6.2308-2317.2004 · Cited by 138
Roberts, P. J., Usary, J. E., Darr, D. B., Dillon, P. M., Pfefferle, A. D., Whittle, M. C., Duncan, J. S., Johnson, S. M., Combest, A. J., Jin, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0563 · Cited by 138
Fiskus, W., Sharma, S., Qi, J., Shah, B., Devaraj, S. G. T., Leveque, C., Portier, B. P., Iyer, S., Bradner, J. E., & Bhalla, K. N. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0258 · Cited by 137
Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK
Tolcher, A. W., Khan, K., Ong, M., Banerji, U., Papadimitrakopoulou, V., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1901 · Cited by 137
Self-citationRAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation
Holderfield, M. T., Merritt, H., Chan, J., Wallroth, M., Tandeske, L., Zhai, H., Tellew, J. E., Hardy, S. F., Hekmat-Nejad, M., Stuart, D. D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.033 · Cited by 134
Sosman, J. A., Kittaneh, M., Lolkema, M. P. J. K., Postow, M. A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., & Kim, K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9009 · Cited by 129
Kim, K., Kong, S., Fulciniti, M., Li, X., Song, W., Nahar, S., Burger, P., Rumizen, M. J., Podar, K., Chauhan, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08127.x · Cited by 126
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Nakamura, A., Arita, T., Tsuchiya, S., Donelan, J., Chouitar, J., Carideo, E., Galvin, K., Okaniwa, M., Ishikawa, T., & Yoshida, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1825 · Cited by 126
Dong, Q., Dougan, D. R., Gong, X., Halkowycz, P., Jin, B., Kanouni, T., O’Connell, S. M., Scorah, N., Shi, L., Wallace, M. B., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.071 · Cited by 124
Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Jing, J., Greshock, J., Holbrook, J. D., Gilmartin, A., Zhang, X., McNeil, E., Conway, T., Moy, C., Laquerre, S., Bachman, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0505 · Cited by 121
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 119
Self-citationBennouna, J., Lang, I., Valladares-Ayerbes, M., Boer, K., Adenis, A., Escudero, P., Kim, T.-Y., Pover, G. M., Morris, C. D., & Douillard, J.-Y. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9392-8 · Cited by 116
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Goetz, E. M., Ghandi, M., Treacy, D. J., Wagle, N., & Garraway, L. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2073 · Cited by 115
Jain, N., Curran, E., Iyengar, N. M., Diaz-Flores, E., Kunnavakkam, R., Popplewell, L., Kirschbaum, M. H., Karrison, T., Erba, H. P., Green, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1311 · Cited by 115
Holt, S. V., Logié, A., Odedra, R., Heier, A., Heaton, S. P., Alferez, D., Davies, B. R., Wilkinson, R. W., & Smith, P. D. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.8 · Cited by 112
Self-citationRAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 110
SQUIRES, M. S., NIXON, P. M., & COOK, S. J. (2002) · Biochemical Journal · doi:10.1042/bj20020372 · Cited by 103
Self-citationFawdar, S., Trotter, E. W., Li, Y., Stephenson, N. L., Hanke, F., Marusiak, A. A., Edwards, Z. C., Ientile, S., Waszkowycz, B., Miller, C. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305207110 · Cited by 101
Information transfer by leaky, heterogeneous, protein kinase signaling systems
Voliotis, M., Perrett, R. M., McWilliams, C., McArdle, C. A., & Bowsher, C. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314446111 · Cited by 98
Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy
Estep, A. L., Palmer, C., McCormick, F. P., & Rauen, K. A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001279 · Cited by 94
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Dai, B., Meng, J., Peyton, M., Girard, L., Bornmann, W. G., Ji, L., Minna, J. D., Fang, B., & Roth, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3647 · Cited by 94
ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest
Todd, D. E., Densham, R. M., Molton, S. A., Balmanno, K., Newson, C., Weston, C. R., Garner, A. P., Scott, L. A., & Cook, S. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207467 · Cited by 92
Self-citationMEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
Duncan, K. E., Chang, L. Y., & Patronas, M. (2015) · Eye · doi:10.1038/eye.2015.82 · Cited by 87
Holt, S. V., Logie, A., Davies, B. R., Alferez, D., Runswick, S., Fenton, S., Chresta, C. M., Gu, Y., Zhang, J., Wu, Y.-L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1780 · Cited by 86
Self-citationMixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
Marusiak, A. A., Edwards, Z. C., Hugo, W., Trotter, E. W., Girotti, M. R., Stephenson, N. L., Kong, X., Gartside, M. G., Fawdar, S., Hudson, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms4901 · Cited by 81
Isshiki, Y., Kohchi, Y., Iikura, H., Matsubara, Y., Asoh, K., Murata, T., Kohchi, M., Mizuguchi, E., Tsujii, S., Hattori, K., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.062 · Cited by 81
Abdel-Wahab, O., Klimek, V. M., Gaskell, A. A., Viale, A., Cheng, D., Kim, E., Rampal, R., Bluth, M., Harding, J. J., Callahan, M. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1038 · Cited by 80
MEK genomics in development and disease
Bromberg-White, J. L., Andersen, N. J., & Duesbery, N. S. (2012) · Briefings in Functional Genomics · doi:10.1093/bfgp/els022 · Cited by 78
Rushworth, L. K., Kidger, A. M., Delavaine, L., Stewart, G., van Schelven, S., Davidson, J., Bryant, C. J., Caddye, E., East, P., Caunt, C. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420159112 · Cited by 75
Self-citationDelaney, A. M., Printen, J. A., Chen, H., Fauman, E. B., & Dudley, D. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.21.7593-7602.2002 · Cited by 75
Murugan, A. K., Dong, J., Xie, J., & Xing, M. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8710 · Cited by 73
Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H. M., Spano, J.-P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0341 · Cited by 71
Leijen, S., Middleton, M. R., Tresca, P., Kraeber-Bodéré, F., Dieras, V., Scheulen, M. E., Gupta, A., Lopez-Valverde, V., Xu, Z.-X., Rueger, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0868 · Cited by 71
A MEK-independent role for CRAF in mitosis and tumor progression
Mielgo, A., Seguin, L., Huang, M., Camargo, M. F., Anand, S., Franovic, A., Weis, S. M., Advani, S. J., Murphy, E. A., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2464 · Cited by 67
Bendell, J. C., Atreya, C. E., André, T., Tabernero, J., Gordon, M. S., Bernards, R., Van Cutsem, E., Tejpar, S., Sidhu, R., Go, W. Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3515 · Cited by 63
Bid, H. K., Kibler, A., Phelps, D. A., Manap, S., Xiao, L., Lin, J., Capper, D., Oswald, D. J., Geier, B., DeWire, M. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0842 · Cited by 62
Self-citationWeekes, C. D., Von Hoff, D. D., Adjei, A. A., Leffingwell, D. P., Eckhardt, S. G., Gore, L., Lewis, K. D., Weiss, G. J., Ramanathan, R. K., Dy, G. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3529 · Cited by 59
Schmieder, R., Puehler, F., Neuhaus, R., Kissel, M., Adjei, A. A., Miner, J. N., Mumberg, D., Ziegelbauer, K. B., & Scholz, A. (2013) · Neoplasia · doi:10.1593/neo.13812 · Cited by 58
Sale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58
Self-citationJuric, D., Soria, J.-C., Sharma, S., Banerji, U., Azaro, A., Desai, J., Ringeisen, F. P., Kaag, A., Radhakrishnan, R., Hourcade-Potelleret, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9051 · Cited by 55
Encyclopedia of Signaling Molecules
Choi, S. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0461-4 · Cited by 54
DNA Methylation As a Clinical Marker in Oncology
Issa, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1016 · Cited by 53
A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
Finn, R. S., Javle, M. M., Tan, B. R., Weekes, C. D., Bendell, J. C., Patnaik, A., Khan, G. N., Laheru, D., Anderson, L., Christy-Bittel, J. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.220 · Cited by 48
LoRusso, P., Shapiro, G., Pandya, S. S., Kwak, E. L., Jones, C., Belvin, M., Musib, L. C., de Crespigny, A., McKenzie, M., Gates, M. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2566 · Cited by 48
Leonowens, C., Pendry, C., Bauman, J., Young, G. C., Ho, M., Henriquez, F., Fang, L., Morrison, R. A., Orford, K., & Ouellet, D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12373 · Cited by 47
TMEM16A alternative splicing coordination in breast cancer
Ubby, I., Bussani, E., Colonna, A., Stacul, G., Locatelli, M., Scudieri, P., Galietta, L. J. V., & Pagani, F. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-75 · Cited by 42
Kelly, K., Mazieres, J., Leighl, N. B., Barlesi, F., Zalcman, G., Gordon, M. S., Reckamp, K. L., Gandara, D. R., Gomez-Roca, C. A., Bennouna, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8027 · Cited by 42
Lee, L., Niu, H., Rueger, R., Igawa, Y., Deutsch, J., Ishii, N., Mu, S., Sakamoto, Y., Busse-Reid, R., Gimmi, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1696 · Cited by 41
Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Mirzoeva, O. K., Collisson, E. A., Schaefer, P. M., Hann, B., Hom, Y. K., Ko, A. H., & Korn, W. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0104 · Cited by 41
Höchster, H. S., Uboha, N. V., Messersmith, W. A., Gold, P. J., O’Neil, B. H., Cohen, D. J., Denlinger, C. S., Cohen, S., Leichman, C. G., Leichman, L., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2609-3 · Cited by 39
Widemann, B. C., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Dombi, E., Baldwin, A. M., Whitcomb, P. O., Martin, S. C., Gillespie, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.10018 · Cited by 39
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo
Robinson, J. P., VanBrocklin, M. W., Lastwika, K. J., McKinney, A. J., Brandner, S., & Holmen, S. L. (2010) · Oncogene · doi:10.1038/onc.2010.513 · Cited by 38
Smith, C. K., & Windsor, W. T. (2007) · Biochemistry · doi:10.1021/bi061893w · Cited by 35
Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor
Lee, P. A., Wallace, E., Marlow, A., Yeh, T., Marsh, V., Anderson, D., Woessner, R., Hurley, B., Lyssikatos, J., Poch, G., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-2515 · Cited by 35
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Infante, J. R., Hamid, O., Messersmith, W. A., DAUD, A. I., Kwak, E. L., Ryan, D. P., Kurzrock, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3517 · Cited by 32
Kurzrock, R., Patnaik, A., Rosenstein, L., Fu, S., Papadopoulos, K. P., Smith, D. A., Falchook, G. S., Chambers, G., Gauvin, J. L., Naing, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3085 · Cited by 28
Gandara, D. R., Hiret, S., Blumenschein, G. R., Barlesi, F., Delord, J.-P., Madelaine, J., Infante, J. R., Reckamp, K. L., Lara, P., Audebert, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8028 · Cited by 27
Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines
Bansal, A., Ramirez, R. D., & Minna, J. D. (1997) · Oncogene · doi:10.1038/sj.onc.1200947 · Cited by 26
Banerjee, A., Jakacki, R. I., Onar‐Thomas, A., Wu, S., Nicolaides, T. P., Turner, D. C., Richardson, S., Poussaint, T. Y., Phillips, J. J., Prados, M. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.10065 · Cited by 23
Cutsem, E. V., Hidalgo, M. M., Bazin, I. S., Canon, J.-L. R., Poddubskaya, E. V., Manojlovic, N. S., Milella, M., Radenkovic, D. V., Verslype, C., Guo, W. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.344 · Cited by 22
Borthakur, G. M., Popplewell, L. L., Kirschbaum, M. H., Foran, J. M., Kadia, T. M., Jabbour, E., Boyiadzis, M. M., Verma, A., Walter, R. B., Wissel, P. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.6506 · Cited by 13
Musib, L. C., Eppler, S., Choo, E. F., Deng, A., Miles, D., Hsu, B. H., Rosen, L. S., Sikic, B. I., LoRusso, P. M., Ma, W., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-1304 · Cited by 12
Becerra, C. R., Infante, J. R., Garbo, L. E., Gordon, M. S., Smith, D. A. B., Braiteh, F. S., Gandara, D. R., Jotte, R. M., Reckamp, K. L., Jankú, F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3023 · Cited by 11
El-Khoueiry, A. B., Kurkjian, C. D., Semrad, T. J., Musib, L. C., Gates, M. R., Eppler, S., Chang, I., Chan, I. T., Rooney, I. A., & Bendell, J. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-b75 · Cited by 10
Houédé, N., Delord, J., Awada, A. H., Lebbé, C., Lesimple, T., Schellens, J. H. M., Rottey, S., Kefford, R. F., von Richter, O., & Raymond, É. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)72397-3 · Cited by 8
Adjei, A. A., LoRusso, P. M., Ribas, A., Sosman, J. A., Dy, G. K., Chmielowski, B., Lipman, P., Zhou, X., Gangolli, E. A., & Bozon, V. A. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)33014-3 · Cited by 4
Cited by
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Metadata
- Authors
- Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J.
- Affiliations
- University of Bath (GB)
- Babraham Institute (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Smith, Paul D.
- Cook, Simon J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-09-24
- Volume
- 15
- Issue
- 10
- Pages
- 577-592
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1848470479
- Cited by
- 606
- References
- 201
- Citations by year
- 2026: 27 · 2025: 44 · 2024: 61 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 47 · 2019: 62 · 2018: 70 · 2017: 66 · 2016: 33 · 2015: 4
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14867)
- Biotechnology and Biological Sciences Research Council (BBS/E/B/0000C199, BBS/E/B/000C0417, BBS/E/B/0000H248, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MEK1 inhibitor, ERK signaling, Raf/MEK/ERK pathway, BRAF mutation, RAS mutations, Raf-1, drug resistance mechanisms, carcinogenesis, cancer therapy
- MeSH terms
- Humans, Neoplasms, Signal Transduction, MAP Kinase Signaling System, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.